Author Bio
Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.
Follow @BiologyFool
Investors can get an early stake in Humacyte, the biotech developing human acellular vessels, by buying shares in
Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC), the special acquisition company (SPAC) that plans to merge with Humacyte. In this video from
Motley Fool Live,
Feb.
22, Fool.com Contributors Brian Orelli and Keith Speights discuss Humacyte's prospects and whether it's more appropriate for a portfolio or a watch list.
Brian Orelli: Moving onto Humacyte, the company is going public through a merger with a special acquisition company (SPAC) called Alpha Healthcare Acquisition. Humacyte is developing a technique to take donor tissue and develop them into blood vessels that can then be used for a variety of uses, including something like dialysis or peripheral artery disease or coronary artery bypass grafts. They've done five phase 2 studies already and they're currently in three different phase 3 studies for different diseases.